1
|
Goepfert A, Barske C, Lehmann S, Wirth E, Willemsen J, Gudjonsson JE, Ward NL, Sarkar MK, Hemmig R, Kolbinger F, Rondeau JM. IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling. Cell Rep 2022; 41:111489. [PMID: 36260993 PMCID: PMC9637376 DOI: 10.1016/j.celrep.2022.111489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 08/20/2022] [Accepted: 09/21/2022] [Indexed: 11/30/2022] Open
Abstract
Signaling through innate immune receptors such as the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily proceeds via the assembly of large membrane-proximal complexes or “signalosomes.” Although structurally distinct, the IL-17 receptor family triggers cellular responses that are typical of innate immune receptors. The IL-17RA receptor subunit is shared by several members of the IL-17 family. Using a combination of crystallographic, biophysical, and mutational studies, we show that IL-17A, IL-17F, and IL-17A/F induce IL-17RA dimerization. X-ray analysis of the heteromeric IL-17A complex with the extracellular domains of the IL-17RA and IL-17RC receptors reveals that cytokine-induced IL-17RA dimerization leads to the formation of a 2:2:2 hexameric signaling assembly. Furthermore, we demonstrate that the formation of the IL-17 signalosome potentiates IL-17-induced IL-36γ and CXCL1 mRNA expression in human keratinocytes, compared with a dimerization-defective IL-17RA variant. IL-17RA is the shared co-receptor for several IL-17 family members. Goepfert et al. show that IL-17 induces IL-17RA dimerization, which then drives the formation of a 2:2:2 hexameric signaling assembly with IL-17RC. Furthermore, IL-17RA dimerization potentiates IL-17 signaling in immortalized primary human keratinocytes, compared with cells expressing a dimerization-defective IL-17RA variant.
Collapse
Affiliation(s)
- Arnaud Goepfert
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Carmen Barske
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Sylvie Lehmann
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Emmanuelle Wirth
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Joschka Willemsen
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | | | - Nicole L Ward
- Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Mrinal K Sarkar
- Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
| | - René Hemmig
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Frank Kolbinger
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Jean-Michel Rondeau
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.
| |
Collapse
|
2
|
Feuerbach D, Schindler P, Barske C, Joller S, Beng-Louka E, Worringer KA, Kommineni S, Kaykas A, Ho DJ, Ye C, Welzenbach K, Elain G, Klein L, Brzak I, Mir AK, Farady CJ, Aichholz R, Popp S, George N, Neumann U. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci Lett 2017; 660:109-114. [PMID: 28923481 DOI: 10.1016/j.neulet.2017.09.034] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 08/22/2017] [Accepted: 09/14/2017] [Indexed: 11/25/2022]
Abstract
Triggering receptor expressed in myeloid cells (TREM2) is a member of the immunoglobulin superfamily and is expressed in macrophages, dendritic cells, microglia, and osteoclasts. TREM2 plays a role in phagocytosis, regulates release of cytokine, contributes to microglia maintenance, and its ectodomain is shed from the cell surface. Here, the question was addressed at which position sheddases cleave TREM2 and what are the proteases involved in this process. Using both pharmacological and genetic approaches we report that the main protease contributing to the release of TREM2 ectodomain is ADAM17, (a disintegrin and metalloproteinase domain containing protein, also called TACE, TNFα converting enzyme) while ADAM10 plays a minor role. Complementary biochemical experiments reveal that cleavage occurs between histidine 157 and serine 158. Shedding is not altered for the R47H-mutated TREM2 protein that confers an increased risk for the development of Alzheimers disease. These findings reveal a link between shedding of TREM2 and its regulation during inflammatory conditions or chronic neurodegenerative disease like AD in which activity or expression of sheddases might be altered.
Collapse
Affiliation(s)
- Dominik Feuerbach
- Neuroscience Research, Novartis Institutes for Biomedical Research, Basel, Switzerland.
| | - Patrick Schindler
- Biologics Center, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Carmen Barske
- Neuroscience Research, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Stefanie Joller
- Neuroscience Research, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Edwige Beng-Louka
- Biologics Center, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Katie A Worringer
- Neuroscience Research, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Sravya Kommineni
- Neuroscience Research, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Ajamete Kaykas
- Neuroscience Research, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Daniel J Ho
- Neuroscience Research, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Chaoyang Ye
- Neuroscience Research, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Karl Welzenbach
- Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Gaelle Elain
- Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Laurent Klein
- Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Irena Brzak
- Neuroscience Research, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Anis K Mir
- Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Christopher J Farady
- Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Reiner Aichholz
- PK Sciences Department, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Simone Popp
- Biologics Center, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Nathalie George
- Biologics Center, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Ulf Neumann
- Neuroscience Research, Novartis Institutes for Biomedical Research, Basel, Switzerland
| |
Collapse
|
3
|
Paganetti P, Reichwald J, Bleckmann D, Abramowski D, Ammaturo D, Barske C, Danner S, Molinari M, Müller M, Papin S, Rabe S, Schmid P, Staufenbiel M. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. Neurobiol Aging 2013; 34:2866-78. [PMID: 23870837 DOI: 10.1016/j.neurobiolaging.2013.06.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Revised: 05/22/2013] [Accepted: 06/18/2013] [Indexed: 11/19/2022]
Abstract
Heterologous expression of the functional amyloid beta (Aβ) antibody β1 in the central nervous system was engineered to maximize antibody exposure in the brain and assess the effects on Aβ production and accumulation in these conditions. A single open reading frame encoding the heavy and light chains of β1 linked by the mouth and foot virus peptide 2A was expressed in brain neurons of transgenic mice. Two of the resulting BIN66 transgenic lines were crossed with APP23 mice, which develop severe central amyloidosis. Brain concentrations at steady-state 5 times greater than those found after peripheral β1 administration were obtained. Similar brain and plasma β1 concentrations indicated robust antibody efflux from the brain. In preplaque mice, β1 formed a complex with Aβ that caused a modest Aβ increase in brain and plasma. At 11 months of age, β1 expression reduced amyloid by 97% compared with age-matched APP23 mice. Interference of β1 with β-secretase cleavage of amyloid precursor protein was relatively small. Our data suggest that severely impaired amyloid formation was primarily mediated by a complex of β1 with soluble Aβ, which might have prevented Aβ aggregation or favored transport out of the brain.
Collapse
Affiliation(s)
- Paolo Paganetti
- Novartis Institutes for Biomedical Research, Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Herzig MC, Bidinosti M, Schweizer T, Hafner T, Stemmelen C, Weiss A, Danner S, Vidotto N, Stauffer D, Barske C, Mayer F, Schmid P, Rovelli G, van der Putten PH, Shimshek DR. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012; 7:e36581. [PMID: 22615783 PMCID: PMC3352901 DOI: 10.1371/journal.pone.0036581] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Accepted: 04/10/2012] [Indexed: 12/30/2022] Open
Abstract
The G2019S mutation in the multidomain protein leucine-rich repeat kinase 2 (LRRK2) is one of the most frequently identified genetic causes of Parkinson’s disease (PD). Clinically, LRRK2(G2019S) carriers with PD and idiopathic PD patients have a very similar disease with brainstem and cortical Lewy pathology (α-synucleinopathy) as histopathological hallmarks. Some patients have Tau pathology. Enhanced kinase function of the LRRK2(G2019S) mutant protein is a prime suspect mechanism for carriers to develop PD but observations in LRRK2 knock-out, G2019S knock-in and kinase-dead mutant mice suggest that LRRK2 steady-state abundance of the protein also plays a determining role. One critical question concerning the molecular pathogenesis in LRRK2(G2019S) PD patients is whether α-synuclein (aSN) has a contributory role. To this end we generated mice with high expression of either wildtype or G2019S mutant LRRK2 in brainstem and cortical neurons. High levels of these LRRK2 variants left endogenous aSN and Tau levels unaltered and did not exacerbate or otherwise modify α-synucleinopathy in mice that co-expressed high levels of LRRK2 and aSN in brain neurons. On the contrary, in some lines high LRRK2 levels improved motor skills in the presence and absence of aSN-transgene-induced disease. Therefore, in many neurons high LRRK2 levels are well tolerated and not sufficient to drive or exacerbate neuronal α-synucleinopathy.
Collapse
Affiliation(s)
- Martin C. Herzig
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Michael Bidinosti
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Tatjana Schweizer
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Thomas Hafner
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Christine Stemmelen
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Andreas Weiss
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Simone Danner
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Nella Vidotto
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Daniela Stauffer
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Carmen Barske
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Franziska Mayer
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Peter Schmid
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Giorgio Rovelli
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - P. Herman van der Putten
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Derya R. Shimshek
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
- * E-mail:
| |
Collapse
|
5
|
Mattes H, Dev KK, Bouhelal R, Barske C, Gasparini F, Guerini D, Mir AK, Orain D, Osinde M, Picard A, Dubois C, Tasdelen E, Haessig S. Corrigendum: Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists. ChemMedChem 2010. [DOI: 10.1002/cmdc.201090046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
6
|
Mattes H, Dev KK, Bouhelal R, Barske C, Gasparini F, Guerini D, Mir AK, Orain D, Osinde M, Picard A, Dubois C, Tasdelen E, Haessig S. Inside Cover: Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists (ChemMedChem 10/2010). ChemMedChem 2010. [DOI: 10.1002/cmdc.201090044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
7
|
Pignot V, Hein AE, Barske C, Wiessner C, Walmsley AR, Kaupmann K, Mayeur H, Sommer B, Mir AK, Frentzel S. Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. J Neurochem 2003; 85:717-28. [PMID: 12694398 DOI: 10.1046/j.1471-4159.2003.01710.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Nogo-66 receptor (NgR) has recently been identified as the neuronal receptor of the myelin-associated proteins Nogo-A, oligodendrocyte protein (OMgp) and myelin-associated glycoprotein (MAG), and mediates inhibition of axonal regeneration both in vitro and in vivo. Through database searches, we have identified two novel proteins (NgRH1 and NgRH2) that turned out to be homologous in their primary structures, biochemical properties and expression patterns to NgR. Like NgR, the homologues contain eight leucine-rich repeats (LRR) flanked by a leucine-rich repeat C-terminus (LRRCT) and a leucine-rich repeat N-terminus (LRRNT), and also have a C-terminal GPI signal sequence. Northern blot analysis showed predominant expression of NgRH1 and NgRH2 mRNA in the brain. In situ hybridization and immunohistochemistry on rat brain slices revealed neuronal expression of the genes. NgRH1 and NgRH2 were detected on the cell surface of recombinant cell lines as N-glycosylated GPI anchored proteins and, consistent with other GPI anchored proteins, were localized within the lipid rafts of cellular membranes. In addition, an N-terminal proteolytic fragment of NgR comprising the majority of the ectodomain was found to be constitutively secreted from cells. Our data indicate that NgR, NgRH1 and NgRH2 constitute a novel receptor protein family, which may play related roles within the CNS.
Collapse
Affiliation(s)
- V Pignot
- Novartis Pharma Research, Basel, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, Escaich S, Kaneshima H, Böhnlein E. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998; 72:1894-901. [PMID: 9499041 PMCID: PMC109480 DOI: 10.1128/jvi.72.3.1894-1901.1998] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The antiviral activities of intracellularly expressed antisense RNAs complementary to the human immunodeficiency virus type 1 (HIV-1) pol, vif, and env genes and the 3' long terminal repeat (LTR) sequence were evaluated in this comparative study. Retroviral vectors expressing the antisense RNAs as part of the Moloney murine leukemia virus LTR promoter-directed retroviral transcript were constructed. The CD4+ T-cell line CEM-SS was transduced with retroviral constructs, and Northern blot analyses showed high steady-state antisense RNA expression levels. The most efficient inhibition of HIV-1 replication was observed with the env antisense RNA, followed by the pol complementary sequence, leading to 2- to 3-log10 reductions in p24 antigen production even at high inoculation doses (4 x 10(4) 50% tissue culture infective doses) of the HIV-1 strain HXB3. The strong antiviral effect correlated with a reduction of HIV-1 steady-state RNA levels, and with intracellular Tat protein production, suggesting that antisense transcripts act at an early step of HIV-1 replication. A lower steady-state antisense RNA level was detected in transduced primary CD4+ lymphocytes than in CEM-SS cells. Nevertheless, replication of the HIV-1 JR-CSF isolate was reduced with both the pol and env antisense RNA. Intracellularly expressed antisense sequences demonstrated more pronounced antiviral efficacy than the transdominant RevM10 protein, making these antisense RNAs a promising gene therapy strategy for HIV-1.
Collapse
Affiliation(s)
- G Veres
- Systemix Inc., a Novartis Company, Palo Alto, California 94304, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Veres G, Escaich S, Baker J, Barske C, Kalfoglou C, Ilves H, Kaneshima H, Böhnlein E. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol 1996; 70:8792-800. [PMID: 8971008 PMCID: PMC190976 DOI: 10.1128/jvi.70.12.8792-8800.1996] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Intracellular expression of antisense transcripts was evaluated for its potential to interfere with human immunodeficiency virus type 1 (HIV-1) replication. Retroviral vectors encoding HIV-1 psi-gag complementary sequences downstream of a selectable gene (neo, puromycin gene, or Lyt2 gene) were stable and yielded high titers. Human CEMSS T cells were transduced with amphotropic retroviral vectors to express RNA complementary to the psi-gag sequence of HIV-1. Replication of laboratory-adapted HIV-1 strains was inhibited by more than 1 order of magnitude (log10) in these transduced cells even at high inoculation doses (4 x 10(4) 50% tissue culture infective doses). Antisense-mediated anti-HIV efficacy was further demonstrated by survival of CD4+ cells in these cultures relative to controls. The level of anti-HIV-1 activity of the psi-gag antisense sequence correlated with the length of the antisense transcript. Maximal anti-HIV efficacy was observed with complementary sequence more than 1,000 nucleotides long, whereas transcripts less than 400 nucleotides long failed to inhibit HIV-1 replication. Expression of psi-gag antisense RNA also reduced HIV-1 JR-CSF replication 10-fold in primary CD4+ lymphocytes. These results obtained with a T-cell line and primary peripheral blood lymphocytes indicate the potential of long antisense RNAs as an efficient anti-HIV-1 therapeutic agent for gene therapy.
Collapse
Affiliation(s)
- G Veres
- Progenesys Program, Systemix Inc., Palo Alto, California 94304, USA
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Junker U, Bevec D, Barske C, Kalfoglou C, Escaich S, Dobrovnik M, Hauber J, Böhnlein E. Intracellular expression of cellular eIF-5A mutants inhibits HIV-1 replication in human T cells: a feasibility study. Hum Gene Ther 1996; 7:1861-9. [PMID: 8894678 DOI: 10.1089/hum.1996.7.15-1861] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Previously, we described two mutants of the cellular Rev co-factor, eukaryotic initiation factor 5A (eIF-5A M13 and M14), which suppress human immunodeficiency virus type 1 (HIV-1) SF2 replication in clonal T cell lines. This study introduced the notion that it is possible to develop gene therapies against infectious agents on the basis of mutant host factors required for viral replication. In this report, we provide further evidence to support this new paradigm and describe murine leukemia virus (MLV)-based retroviral vectors expressing three different eIF-5A mutants from the viral long terminal repeat (LTR). HIV-1 replication (SF2, HXB-3) was reduced up to 2 orders of magnitude in transduced, polyclonal T cell populations. All eIF-5A mutants also showed antiviral activity (approximately seven-fold reduction) in a chronic HIV-1 infection model. Expression of eIF-5A mutant M13 delta in peripheral blood lymphocytes (PBLs) showed no difference in proliferation and metabolic activity as determined in a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)-assay, suggesting that expression of this type of mutant protein is not associated with cellular toxicity. In summary, these data suggest that gene therapy for HIV-1 infection can be developed on the basis of mutants of the Rev co-factor eIF-5A.
Collapse
Affiliation(s)
- U Junker
- Progenesys program at Systemix, Palo Alto, CA 94304
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Ilves H, Barske C, Junker U, Böhnlein E, Veres G. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene 1996; 171:203-8. [PMID: 8666273 DOI: 10.1016/0378-1119(96)00075-3] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Retroviral gene delivery systems for RNA polymerase II (RNA pol II)-based promoters have been developed and are widely used in gene transfer studies. In contrast, gene delivery systems with RNA pol III-based expression cassettes have not been studied comprehensively, although therapeutic applications (e.g., ribozymes, antisense, triplex RNA and RNA decoys) have been proposed. In this report, we describe retroviral vectors designed to optimize expression of short chimeric RNAs transcribed from a number of RNA pol III promoters. Our results show that all analysed RNA pol III expression cassettes (tRNA, U6, Ad VA1), regardless of orientation, do not transcribe efficiently when located between the retroviral long terminal repeats (LTRs). In contrast, high steady-state expression levels can be achieved by inserting the RNA pol III expression cassette into the U3 region of the LTR (double-copy design). Compared to human tRNA gene promoters (tRNA(Met), tRNA(Val)), the human small nuclear RNA U6 gene (U6) and the adenovirus virus-associated RNA 1 (Ad VA1) gene promoters yielded higher expression levels. The majority of the chimeric U6-derived transcripts were detected in the nuclear RNA fraction, and the VA1 and tRNA-driven transcripts were predominantly detected in the cytoplasmic compartments. This report is the first comparative study of RNA pol III-driven promoters expressing short chimeric transcripts leading to an optimized retroviral-vector design.
Collapse
MESH Headings
- Adenoviridae/genetics
- Animals
- Cell Line
- Gene Products, rev/genetics
- Genetic Vectors/chemistry
- Genetic Vectors/genetics
- HIV/genetics
- HeLa Cells
- Humans
- Mice
- Promoter Regions, Genetic
- RNA Polymerase III/biosynthesis
- RNA Polymerase III/genetics
- RNA, Catalytic/genetics
- RNA, Transfer, Met/genetics
- RNA, Transfer, Val/genetics
- RNA, Viral
- Recombinant Proteins/genetics
- Retroviridae/genetics
- Ribonucleoprotein, U4-U6 Small Nuclear/genetics
- Subcellular Fractions
- Transcription, Genetic
- Transcriptional Activation
- Transduction, Genetic
- rev Gene Products, Human Immunodeficiency Virus
Collapse
Affiliation(s)
- H Ilves
- Systemix Inc., Department of Molecular Therapy, Palo Alto, CA 94304, USA
| | | | | | | | | |
Collapse
|